1 2 3	A Systematic Review and Meta-Analysis on the Effectiveness of Bivalent mRNA Booster Vaccines against Omicron Variants
4 5	Shangchen Song ^{1,†} , Zachary J. Madewell ^{1,†} , Mingjin Liu ² , Yu Miao ^{2,} , Shaolin Xiang ² , Yanan Huo ³ , Shoumi Sarkar ¹ , Amily Chowdhury ⁴ , Ira M. Longini, Jr. ^{1,#} , Yang Yang ^{2,#,*}
6 7	¹ Department of Biostatistics, College of Public Health and health Professions, University of Florida, Gainesville, FL, USA
8 9	² Department of Statistics, Franklin College of Arts and Sciences, University of Georgia, Athens, GA, USA
10	³ Gilead Sciences, Inc, Foster City, CA, USA
11 12 13	⁴ Department of Computer Science, Franklin College of Arts and Sciences, University of Georgia, Athens, GA, USA
14 15 16	[†] These authors share first authorship [#] These authors share senior authorship
17 18 19 20 21 22 23	 * Correspondence should be addressed to: Prof. Yang Yang Email: <u>yang.yang4@uga.edu</u> Keywords: Bivalent; Omicron; Vaccine Effectiveness; Meta-Analysis; Infection; Severe disease
24 25 26 27	ABSTRACT Background: A global shift to bivalent mRNA vaccines is ongoing to counterbalance diminishing monovalent vaccine effectiveness (VE) due to the evolution of SARS-CoV-2 variants, yet substantial variation in the bivalent VE exists across studies and a complete picture is lacking.
28 29 30 31	Methods: We searched papers evaluating SARS-CoV-2 bivalent mRNA vaccines on PubMed, Web of Science, Cochrane Library, Google Scholar, Embase, Scopus, bioRxiv, and medRxiv published from September 1st, 2022, to November 8th, 2023. Pooled VE against Omicron-associated infection and severe events was estimated in reference to unvaccinated, ≥ 2 monovalent doses, and ≥ 3 monovalent doses.
32 33 34 35 36 37 38 39 40	Results: From 630 citations identified, 28 studies were included, involving 55,393,303 individuals. Bivalent boosters demonstrated superior protection against symptomatic or any infection compared to unvaccinated, ≥ 2 monovalent doses, and ≥ 3 monovalent doses, with corresponding relative VE estimated as 53.5% (95% CI: 22.2-82.3%), 30.8% (95% CI: 22.5-38.2%), and 28.4% (95% CI: 10.2-42.9%) for all ages, and 22.5% (95% CI: 16.8-39.8%), 31.4% (95% CI: 27.7-35.0%), and 30.6% (95% CI: -13.2-57.5%) for adults ≥ 60 years old. Pooled bivalent VE estimates against severe events were higher, 72.9% (95% CI: 60.5-82.4%), 57.6% (95% CI: 42.4-68.8%), and 62.1% (95% CI: 54.6-68.3%) for all ages, and 72.0% (95% CI: 51.4-83.9%), 63.4% (95% CI: 41.0-77.3%), and 60.7% (95% CI: 52.4-67.6%) for adults ≥ 60 years old, compared to unvaccinated, ≥ 2 monovalent doses, and ≥ 3 monovalent doses, respectively.

- **Conclusions:** Bivalent boosters demonstrated higher VE against severe outcomes than monovalent boosters across age groups, highlighting the critical need for improving vaccine coverage, especially among the vulnerable older subpopulation.

45 Introduction

46 The emergence of the SARS-CoV-2 Omicron (B.1.1.529) variant in late 2022 significantly 47 undermined previous control measures in the continuing COVID-19 pandemic. Despite significant progress in 48 vaccination efforts worldwide. Omicron continues to pose a substantial threat, causing a significant number of 49 severe COVID-19 cases and fatalities due to continuously evolving immune escape. Monovalent mRNA 50 vaccines, initially designed for ancestral SARS-CoV-2 variants, demonstrated high effectiveness in preventing 51 severe COVID-19 caused by the Omicron variants [1,2]. One or two monovalent mRNA booster doses also 52 reduced hospitalizations and fatalities [3]. However, their effectiveness waned over time, particularly against 53 Omicron [4,5]. The Omicron sub-lineages from BA.1 to BA.5 and subsequent variants such as XBB.1.5, EG.5, 54 and FL.1.5.1 showcased the virus's adaptability through genetic mutations in the spike protein, making it 55 increasingly distinct from the original wild type [6]. Laboratory studies demonstrated that antibodies were less 56 effective at neutralizing these emerging subvariants compared to ancestral variants [7,8]. 57 In response to reduced effectiveness of monovalent boosters, bivalent mRNA booster vaccines 58 containing spike sequences from the original SARS-CoV-2 strain and Omicron subvariants (BA.1 or BA.4-5) 59 emerged as a potential strategy to enhance protection against severe clinical outcomes. Laboratory studies demonstrated that bivalent vaccines significantly increased neutralizing activity against subvariants like BA.4, 60 61 BA.5, BA.2.75, BQ.1.1, and XBB compared to the monovalent vaccines [9,10]. On September 1, 2022, the Advisory Committee on Immunization Practices (ACIP) recommended these vaccines to address the reduced 62 63 effectiveness of monovalent vaccines [11]. The U.S. Food and Drug Administration (FDA) subsequently 64 approved Moderna and Pfizer-BioNTech bivalent formulations as single booster doses for individuals who 65 completed primary vaccination series or received monovalent boosters [12]. Since September 2022, many 66 countries have transitioned from monovalent boosters to bivalent boosters. 67 Recent studies increasingly demonstrate the higher effectiveness for bivalent boosters compared to 68 monovalent vaccines against infection and severe disease [13–15]. Meta-analyses provide an integrative

assessment of the effectiveness of bivalent boosters by aggregating data from multiple studies, enhancing statistical robustness and generalizability, while controlling for differences between individual studies. One review and case study reported vaccine effectiveness (VE) for bivalent boosters against hospitalization and infection, but was limited to a few early studies [16]. Herein, we synthesize contemporary literature to report absolute and relative VE of bivalent boosters against infection and severe COVID-19 compared to no vaccination, two or more monovalent doses, and three or more monovalent doses, respectively.

15

76 Methods

This analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) reporting guidelines.

79

80 Data Sources and Searches

81 We systematically searched databases and platforms including PubMed, Web of Science, Cochrane 82 Library, Google Scholar, Embase, Scopus, and preprint servers (bioRxiv and medRxiv) for papers published 83 between September 1st, 2022 and November 8th, 2023. We applied Boolean combinations of the following keywords to identify relevant publications: "SARS-CoV-2", "COVID-19", "2019nCoV", "bivalent booster", 84 85 "effectiveness", "efficacy", "test-negative", "case-control", "cohort study", "Omicron", "infection", "infected", "hospitalization", "hospital admission". Details about the search procedures are available in 86 87 Supplementary material A.1. Publication language was not restricted, and reference lists of selected papers 88 were also screened for additional studies.

89

90 Study Selection

Studies were chosen based on the PICOS (Participant, Intervention, Comparator, Outcome, Study 91 92 Type) criteria [17] as detailed in Supplementary Material A.2. We focused on original research using 93 observational studies, e.g., test-negative design study or cohort study, that reported estimates for the 94 effectiveness of COVID-19 bivalent boosters against Omicron-related infections or severe events in reference 95 to either no vaccination or monovalent vaccine doses. The COVID-19 bivalent boosters include BA.1 type and 96 BA.4/BA.5 type mRNA vaccines manufactured by Pfizer-BioNTech and Moderna. We excluded studies that 97 (i) did not assess VE (e.g., evaluated neutralizing antibodies); (ii) targeted special populations (e.g., patients 98 with kidney disease); (iii) focused on relative VE between different types or doses of bivalent vaccines; (iv) 99 reported VE results for a mixture of bivalent and monovalent vaccines (unless bivalent representation was 100 90% or higher); or (v) examined outcomes unrelated to COVID-19. Our analysis included all available age 101 groups, and we did not seek additional data from authors.

After duplicates were removed, studies were initially sifted based on titles and abstracts by three independent teams, each with three researchers. Full texts of potential matches were then independently reviewed by the same three teams. Any disagreements were discussed until a consensus was reached. Preprints were checked and updated with their most recently published version if available as of January 5th, 2024. Zotero was used for literature management.

107

108 Data Extraction and Quality Assessment

109 The following information was independently extracted from the included studies: title, authors, 110 publishing journal and year, study region, duration and design, statistical method, definition of VE, circulating 111 subvariants, types and doses of bivalent and reference vaccines, time from vaccination to testing, age group, 112 adjusted VE point estimate and 95% confidence intervals, and confounders adjusted for. When available, the 113 raw numbers of vaccinated and unvaccinated individuals among cases and controls were also recorded. 114 Study quality and risk of bias of each study were independently assessed by three researchers using 115 the Newcastle-Ottawa Scale (NOS). Studies were assigned up to 9 points according to participant selection (4 116 points), study comparability (1 point), and outcome of interest (4 points). A score >7 was considered as high 117 quality, 5-6 as medium, and <5 as low, and studies classified as low quality were excluded from the meta-118 analysis. Publication bias was also evaluated by Egger's test, Begg and Mazumdar rank correlation, and funnel 119 plots when at least ten studies were available, with statistical significance achieved if p-value < 0.1. Upon 120 detection of publication bias, we used the Duval and Tweedie trim-and-fill method [18] to adjust the analysis, 121 where missing effect sizes were imputed to achieve symmetry.

122

123 Data Synthesis and Analysis

124 We grouped bivalent VEs into three categories based on the reference arm: (1) unvaccinated, (2) two 125 doses of monovalent vaccines, and (3) three or more doses of monovalent vaccines. This categorization aimed 126 to assess VE variations across different previous vaccination benchmarks. Notably, due to the recent 127 introduction of bivalent vaccines, most VE estimates from the studies we gathered pertain to short-term 128 effects, typically within 120 days. If a study reported VE estimates for more granular time intervals than 129 desired, we combined these estimates using an inverse variance weighted (IVW) averaging method to 130 synthesize a VE estimate for the desired time interval. For example, if a study reported VE estimates for age 131 groups 60–69 years, 70–79 years and \geq 80 years old, we synthesize the three VE estimates into a single 132 measure for individuals aged ≥ 60 years old. We evaluated VE for the entire vaccine-eligible population, 133 pooling all age groups, and specifically for senior adults aged 60 and above. We assessed VE against the 134 Omicron subvariants for both infections and severe outcomes. We did not distinguish between any infection 135 and symptomatic infection, even though some studies focused on the latter; the implications of this approach 136 are discussed. Severe outcomes are defined as hospitalization or death. We did not differentiate between the 137 two types/manufacturers of bivalent vaccines as most studies reported combined VE for these vaccines.

138 To increase sample size, we pooled VE estimates from both test-negative studies and cohort studies. 139 Test-negative studies used either conditional logistic regression or multivariate logistic regression with 140 calendar time adjustment, whereas cohort studies mostly used Cox regression. Notably, simulation results in a 141 previous study showed that logistic regression adjusting for calendar time closely approximated conditional 142 logistic regression matched on calendar time, and the latter shares the same form as the partial likelihood of 143 Cox regression [19]. In cases where studies did not directly report VE but provided Odds Ratios (OR) or 144 Hazard Ratios (HR), VE was derived using the formulas: $(1 - OR) \times 100\%$ or $(1 - HR) \times 100\%$, respectively. 145 We computed pooled VE estimates and their corresponding 95% confidence intervals using a random-effect 146 meta-analysis with restricted maximum likelihood estimation. To assess between-study heterogeneity, we employed the I^2 statistic, with thresholds of 25%, 50%, and 75% denoting low, moderate, and high 147

heterogeneity, respectively. All statistical procedures and visual representations were conducted using the
 metafor R package (version 4.0.5) [20].

150

151

152 **Results**

153 Study selection and characteristics

We obtained 630 articles from all searched databases (18 from PubMed, 6 from Web of Science, 29 from Embase, 425 from Scopus, 2 from Cochrane Library, 46 from medRxiv, 4 from bioRxiv, and 100 from Google Scholar). After removing duplicates, 539 articles remained, of which 87 passed the screening of title, abstracts and keywords and underwent full text review. After further quality control such as removing duplicates and special populations, of these 87 articles as well as 2 additional articles identified through reference lists of eligible articles, 28 articles [13–15,21–45] were formally included in this meta-analysis (Figure 1).

161 Among the 28 papers, nine studies were conducted in the U.S., three in the U.K., three in Italy, two in 162 each of Canada, Japan, Korea, one in each of France, Israel, Netherlands, Norway, Qatar and Singapore, and a 163 multi-national study conducted across Denmark, Finland, Norway, and Sweden. There were 12 test-negative 164 design studies and 16 cohort studies. Regarding the Omicron subvariants in circulation, 20, 13, and 16 studies 165 involved BA.4/5, BQ, and XBB lineages, respectively. Most studies reported multiple VE estimates, stratified 166 by the type of vaccine or the type of outcome. In total, there were 456 VE estimates, including 219 for the 167 BA.1 bivalent booster, 191 for BA.4/5 bivalent booster, and 46 for mixed cohorts receiving BA.1 or BA.4/5 168 bivalent boosters. By the type of outcome, 36, 64, and 356 VE estimates were reported for symptomatic 169 infection, any infection, and severe events, respectively. After screening and synthesizing VE estimates, 20 170 were available for calculating the pooled VE against symptomatic or any infection and 31 for the pooled VE 171 against severe outcomes. In all included studies, the number of doses of bivalent boosters are greater or equal 172 to the number of doses of the reference vaccination regimens, which included unvaccinated, monovalent full 173 course (two doses of monovalent vaccines), and monovalent boosters (3-4 doses of monovalent vaccines).

174

175 Vaccine effectiveness against Omicron symptomatic infection or any infection

The VE estimates for the bivalent boosters against Omicron symptomatic or any infection were summarized for all age groups combined in Figure 2 and for seniors aged 60 years or older in Figure 3. Only two studies reported a bivalent booster VE with unvaccinated as the reference, with a large inter-study difference, and the combined VE was 53.5% (95% CI: -22.2–82.3%) for adults aged 16 or over (Fig. 2). When the reference was monovalent full course (2 monovalent doses), the pooled bivalent VE from seven studies was 30.8% (95% CI: 22.5–38.2%) for all ages. When the reference was monovalent boosters (3 or more monovalent doses), the pooled bivalent VE from seven studies was estimated to be 41.8% (95% CI: 9.0–

- 183 62.8%) for all adults ≥ 18 years (Fig. 2). The large uncertainty of this VE estimate came from the study of Tan
- et al. (2023) in Singapore which reported a VE against symptomatic infection of 83.0% with a tight 95% CI of
- 185 82.0–84.0%, much higher than the other studies (I^2 statistic=99%). After excluding this study, the pooled VE
- 186 for all ages was 28.4% (95% CI: 10.2–42.9%). For seniors over 60, one study in the U.S., Rudolph, et al.
- 187 (2023), reported bivalent VE estimates against the unvaccinated and those with ≥ 2 monovalent doses as 22.5%
- 188 (95% CI: 16.8–39.8%) and 31.4% (95% CI: 27.7–35.0%), respectively (Fig. 3). When considering \geq 3
- 189 monovalent doses as a reference, the pooled VE from four studies was 49.0% (95% CI: -2.1–74.5%), but
- excluding Tan et al. (2023), it was 30.6% (95% CI: -13.2–57.5%). Combining all three reference vaccination
- 191 groups, the pooled overall VE against symptomatic or any infection was estimated to be 38.7% (95% CI:
- 192 23.6–50.8%) for all ages and 42.5% (95% CI: 8.6–63.9%) for adults aged 60 years or older or, if excluding the
- Singapore study, 32.4% (95% CI: 22.6–41.0%) for all ages and 29.3% (95% CI: 7.2–46.1%, 5 studies) for
 seniors (Fig. 3).
- 195

196 Vaccine Effectiveness against Omicron-associated Severe Events

- 197 The pooled bivalent VE estimates against Omicron-associated severe events for all ages were 72.9% 198 (95% CI: 60.5–82.4%, 7 studies), 57.6% (95% CI: 42.4–68.8%, 8 studies), and 68.5% (95% CI: 56.4–77.2%, 199 10 studies) when the reference group was unvaccinated, ≥ 2 monovalent doses, and ≥ 3 monovalent doses, 200 respectively (Fig. 4). In the third category, the pooled VE excluding Tan et al. (2023), which also reported a 201 higher VE estimate against severe events than the rest studies, was 62.1% (95% CI: 54.6–68.3%, 9 studies). 202 Combining the three reference groups, the overall pooled VE against severe events was estimated to be 66.5% 203 (95% CI: 59.2–72.6%, 25 studies) for all ages, or 64.7% (95% CI: 57.7–70.6%, 24 studies) when excluding 204 Tan et al. (2023). For those aged 60 or over, the pooled bivalent VE estimates were 72.0% (95% CI: 51.4-205 83.9%, 4 studies), 63.4% (95% CI: 41.0–77.3%, 3 studies), and 60.7% (95% CI: 52.4–67.6%, 8 studies) when 206 the reference group was unvaccinated, ≥ 2 monovalent doses, and ≥ 3 monovalent doses, respectively (Fig. 5). 207 The pooled bivalent VE estimates combining all reference groups was 65.2% (95% CI: 57.4–71.5%, 15 208 studies) for senior adults.
- 209

210 Assessment of Publication Bias

- The only detected publication bias was in the pooled estimate of the overall VE of the bivalent boosters against severe events in all age groups (Egger's test p = 0.097, Begg's test p = 0.236) as shown in Figure 6. Results were corrected for these biases using the trim-and-fill method.
- 214

215 **Discussion**

In this systematic review and meta-analysis, we synthesized the available evidence from 28 studies,
involving 55,393,303 individuals. We found that the bivalent COVID-19 booster doses (vaccinated as the third

- 218 or subsequent doses) in addition to the previous COVID-19 vaccine series provided about 30-50% VE against
- 219 infection or symptomatic infection with Omicron subvariants, in reference to unvaccinated or monovalent dose
- regimens. The bivalent VE against severe clinical outcomes appeared to be more robust, reaching 60-70% for 220
- 221 various reference groups. These results underscore the importance of swift adaption of vaccine development to
- 222 the evolutional path of the SARS-CoV-2 family. These real-world findings resonate with early
- 223 immunogenicity studies showing higher antibody responses induced by the bivalent vaccines compared to the
- 224 monovalent vaccines [46-48].
- 225 A notable observation from our analysis is that the bivalent vaccine efficacies among individuals aged 226 \geq 60 years were similar to those among the general population. For symptomatic or any infection, the VE 227 estimates for bivalent vs. \geq 3 monovalent (excluding the Singapore study) were 28.4% for all ages and 30.6% 228 for seniors. For severe outcomes, the VE estimates for bivalent were comparable between all ages and ≥ 60 229 years regardless of the reference group, e.g., 72.9% and 72.0% for bivalent vs. unvaccinated, and 57.6% and 230 63.4% for bivalent vs. ≥ 2 monovalent. The VE of bivalent vs. ≥ 3 monovalent doses was also comparable 231 between the two age profiles (62.1% after excluding the Singapore study vs. 60.7%). However, with most 232 studies (8 out of 10) for all-age VE estimates conducted among seniors, this similarity could be partly 233 attributed to the similarity in age profiles. Given that the senior age group is the most vulnerable to severe 234 outcomes from COVID-19 [49], our findings suggest we should continue to prioritize the older subpopulation for coverage with bivalent vaccines. 235
- 236 Compared to three or more doses of a monovalent vaccine, the bivalent booster vaccines demonstrated 237 superior relative efficacies against both infection (VE=28-42% depending on excluding or including the 238 Singapore study) and severe disease (VE=68.5%) during the circulation of the BA.4, BA.5, and subsequent 239 Omicron subvariants. This superiority can also be seen by calculating the relative efficacy of three or more 240 doses of monovalent vs. unvaccinated. For example, in terms of severe disease, the relative efficacy of three or more doses of monovalent vs. unvaccinated is $1 - \frac{1 - 0.729}{1 - 0.685} = 0.14$, much lower than the relative efficacy of the 241 242 bivalent booster vs. unvaccinated, 0.729.
- 243 Our study has several limitations. First, our analysis was constrained by the lack of long-term data, 244 limiting our ability to assess the potential waning of VE over time. Some studies have shown the efficacy of 245 the bivalent booster dose waned over time, similar to the monovalent booster doses [14,50], but the VE against 246 severe outcomes generally wanes at a much slower rate than that against infection. Second, a few studies 247 found prior infection could modify the efficacies of monovalent or bivalent boosters [37,50], but we were 248 unable to stratify the VE estimates by prior infection status as most studies did not provide such information. 249 Third, many studies included in this meta-analysis [21,22,29,32] did not specify the manufacturer or type of 250 the bivalent booster and monovalent doses, introducing additional heterogeneity into and thus complicating the 251
 - interpretation of our pooled results. This lack of granularity emphasizes the need for future studies to report

VE estimates with greater specificity. Finally, we had to synthesize desired VE measures from multiple VE estimates in the same study, e.g., deriving the VE for the age group of 60 years or more from VE estimates for finer age groups. Such synthesis did not consider potential correlation among the finer estimates, which could result in under-evaluation of uncertainty in the synthesized VE estimate.

256 In conclusion, our study presents a systematic and up-to-date picture of the protective benefits of 257 bivalent COVID-19 booster doses against Omicron subvariants, particularly against severe clinical outcomes. 258 The SARS-CoV-2 pandemic continues to evolve with newly emerging variants that can better evade the 259 current immunity landscape of the population but are not necessarily more pathogenic, e.g., HV.1 and JN.1 260 Omicron lineages have dominated previous strains in many places. While updated vaccines are rolling out at a 261 slower pace, their strong protection against severe disease induced by the new strains has saved millions of lives and guards our daily life from interruption. On the other hand, as of September 2023, the coverage of 262 263 bivalent vaccines in the U.S. remained below 50% even among people aged >60 years, according to the U.S. 264 CDC. In September 2023, US CDC recommended vaccination with XBB-containing vaccines among persons 265 aged ≥ 6 months [51]. In addition to developing more potent and convenient vaccines such as the flu-Covid 266 combo vaccines, more resources should be directed to campaign the effectiveness and safety of existing 267 bivalent vaccines, especially among the vulnerable subpopulations. Finally, we encourage future research on 268 vaccine effectiveness assessment to provide more granular VE data and to monitor the long-term safety and 269 effectiveness of bivalent/multivalent vaccines.

270

271 Author Contributions

SSong, ZM, YY and IL conceived the study. SSong and ZM collected the data, SSong, ZM, ML, YM,
SX, YH, SSarkar, AC and YY reviewed the data. SSong analyzed data under the supervision of YY, ZM and
IL. SSong, ZM and YY drafted the manuscript. All authors contributed to interpretation of results. SSong, YY,
ZM and IL finalized the manuscript.

276

277 **Conflicts of Interest**

The authors declare that the research was conducted in the absence of any commercial or financialrelationships that could be construed as a potential conflict of interest.

280

281 **Data Sharing**

The raw summary-level data were derived from publicly available papers cited in the reference.
Extracted data and programming codes will be made available upon request by email to the corresponding author.

285

286 Funding/Support

287 SSong, YY and IL were supported by US CDC grant U01 CK000670.288

289 Role of the Funding Source

- 290 The funders had no role in study design, data collection, data analysis, data interpretation, or the
- 291 writing of the report.

292 **References**

- 2931.Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a294literature review and meta-analysis. International Journal of Infectious Diseases **2022**; 114:252–260.
- Ssentongo P, Ssentongo AE, Voleti N, et al. SARS-CoV-2 vaccine effectiveness against infection,
 symptomatic and severe COVID-19: a systematic review and meta-analysis. BMC Infectious Diseases
 2022; 22:439.
- Song S, Madewell ZJ, Liu M, Longini IM, Yang Y. Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies.
 Frontiers in Public Health 2023; 11. Available at: https://www.frontiersin.org/articles/10.3389/fpubh.2023.1195908. Accessed 8 October 2023.
- 3024.Menegale F, Manica M, Zardini A, et al. Evaluation of Waning of SARS-CoV-2 Vaccine–Induced303Immunity: A Systematic Review and Meta-analysis. JAMA Network Open **2023**; 6:e2310650.
- Madewell ZJ, Yang Y, Longini IM Jr, Halloran ME, Dean NE. Household Secondary Attack Rates of SARS CoV-2 by Variant and Vaccination Status: An Updated Systematic Review and Meta-analysis. JAMA
 Network Open **2022**; 5:e229317.
- Chatterjee S, Bhattacharya M, Nag S, Dhama K, Chakraborty C. A Detailed Overview of SARS-CoV-2
 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological
 Landscape, Immune Escape, and Therapies. Viruses **2023**; 15:167.
- Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4
 and BA.5. Nature **2022**; 608:603–608.
- Planas D, Bruel T, Staropoli I, et al. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to
 neutralizing antibodies. Nat Commun **2023**; 14:824.
- Hyun H-J, Choi M-J, Nham E, et al. Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent
 COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations.
 Vaccines 2023; 11:1320.
- Davis-Gardner ME, Lai L, Wali B, et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA
 Bivalent Booster. N Engl J Med **2023**; 388:183–185.
- Rosenblum HG. Interim Recommendations from the Advisory Committee on Immunization Practices for
 the Use of Bivalent Booster Doses of COVID-19 Vaccines United States, October 2022. MMWR Morb
 Mortal Wkly Rep 2022; 71. Available at: https://www.cdc.gov/mmwr/volumes/71/wr/mm7145a2.htm.
 Accessed 8 October 2023.
- Commissioner O of the. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech
 Bivalent COVID-19 Vaccines for Use as a Booster Dose. FDA, 2022. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes moderna-pfizer-biontech-bivalent-covid-19-vaccines-use. Accessed 8 October 2023.
- 13. Chae C, Kim RK, Jang EJ, et al. Comparing the effectiveness of bivalent and monovalent COVID-19
 vaccines against COVID-19 infection during the winter season of 2022-2023: A real-world retrospective

- 329 observational matched cohort study in the Republic of Korea. International Journal of Infectious 330 Diseases 2023; 135:95-100. 331 14. Lin D-Y, Xu Y, Gu Y, Zeng D, Sunny SK, Moore Z. Durability of Bivalent Boosters against Omicron 332 Subvariants. New England Journal of Medicine 2023; 388:1818–1820. 333 15. Link-Gelles R, Weber ZA, Reese SE, et al. Estimates of Bivalent mRNA Vaccine Durability in Preventing 334 COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without 335 Immunocompromising Conditions - VISION Network, September 2022-April 2023. MMWR Morb Mortal 336 Wkly Rep 2023; 72:579-588. 337 16. Meah S, Shi X, Fritsche LG, et al. Design and analysis heterogeneity in observational studies of COVID-19 338 booster effectiveness: A review and case study. Science Advances 2023; 9:eadj3747. 339 17. Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a 340 comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. 341 BMC Health Serv Res 2014; 14:579. 18. 342 Duval S, Tweedie R. Trim and Fill: A Simple Funnel-Plot-Based Method of Testing and Adjusting for 343 Publication Bias in Meta-Analysis. Biometrics 2000; 56:455–463. 344 BOND HS, SULLIVAN SG, COWLING BJ. Regression approaches in the test-negative study design for 19. 345 assessment of influenza vaccine effectiveness. Epidemiol Infect 2016; 144:1601–1611. 346 20. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. Journal of Statistical 347 Software **2010**; 36:1–48. 348 Andersson NW, Thiesson EM, Baum U, et al. Comparative effectiveness of bivalent BA.4-5 and BA.1 21. 349 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study. 350 BMJ 2023; 382:e075286. 351 22. Arashiro T, Arima Y, Kuramochi J, et al. Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent 352 COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period 353 in Japan. Open Forum Infect Dis 2023; 10:ofad240. 354 Arbel R, Peretz A, Sergienko R, et al. Effectiveness of a bivalent mRNA vaccine booster dose to prevent 23. 355 severe COVID-19 outcomes: a retrospective cohort study. The Lancet Infectious Diseases 2023; 23:914-356 921. 357 Auvigne V, Tamandjou Tchuem CR, Schaeffer J, Vaux S, Parent Du Chatelet I. Protection against 24. 358 symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine 359 compared to the mRNA Original monovalent vaccines – A matched cohort study in France. Vaccine 360 **2023**; 41:5490–5493. 361 Chatzilena A, Hyams C, Challen R, et al. Relative vaccine effectiveness of mRNA COVID-19 boosters in 25. 362
- people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter
 (bivalent vaccine) booster campaigns: a prospective test negative case-control study, United Kingdom,
 2022. Eurosurveillance **2023**; 28:2300173.

- 26. Chemaitelly H, Ayoub HH, AlMukdad S, et al. Bivalent mRNA-1273.214 vaccine effectiveness against
 366 SARS-CoV-2 omicron XBB* infections. Journal of Travel Medicine **2023**; 30:taad106.
- Fabiani M, Mateo-Urdiales A, Sacco C, et al. Protection against severe COVID-19 after second booster
 dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since
 infection, Italy, 12 September to 11 December 2022. Eurosurveillance 2023a; 28:2300105.
- Grewal R, Buchan SA, Nguyen L, et al. Effectiveness of mRNA COVID-19 Monovalent and Bivalent
 Vaccine Booster Doses Against Omicron Severe Outcomes Among Adults Aged ≥50 Years in Ontario,
 Canada: A Canadian Immunization Research Network Study. The Journal of Infectious Diseases 2023;
 :jiad419.
- Huiberts AJ, de Gier B, Hoeve CE, et al. Effectiveness of bivalent mRNA booster vaccination against
 SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022. Euro Surveill 2023;
 28:2300087.
- 30. Kirsebom FCM, Andrews N, Stowe J, Ramsay M, Bernal JL. Duration of protection of ancestral-strain
 monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in
 England: a test-negative case-control study. The Lancet Infectious Diseases 2023a; 0. Available at:
 https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00365-1/fulltext. Accessed 30
 September 2023.
- 382 31. Kirsebom FCM, Harman K, Lunt RJ, et al. Vaccine effectiveness against hospitalisation estimated using a
 383 test-negative case-control study design, and comparative odds of hospital admission and severe
 384 outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England. The Lancet Regional
 385 Health Europe 2023b; 35. Available at: https://www.thelancet.com/journals/lanepe/article/PIIS2666 386 7762(23)00174-6/fulltext. Accessed 5 January 2024.
- 387 32. Lee N, Nguyen L, Austin PC, et al. Protection Conferred by COVID-19 Vaccination, Prior SARS-CoV-2
 388 Infection, or Hybrid Immunity Against Omicron-Associated Severe Outcomes Among Community 389 Dwelling Adults. Clinical Infectious Diseases **2023**; :ciad716.
- 33. Mateo-Urdiales A, Sacco C, Fotakis EA, et al. Relative effectiveness of monovalent and bivalent mRNA
 boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post administration in people aged 60 years or older in Italy: a retrospective matched cohort study. The
 Lancet Infectious Diseases **2023**; Available at:
- https://www.sciencedirect.com/science/article/pii/S1473309923003742. Accessed 1 October 2023.
- 34. Shrestha NK, Burke PC, Nowacki AS, Simon JF, Hagen A, Gordon SM. Effectiveness of the Coronavirus
 Disease 2019 Bivalent Vaccine. Open Forum Infectious Diseases 2023; 10:ofad209.
- 397 35. Stecher M, Kristoffersen AB, Lie K, Andersen SR, Meijerink H, Starrfelt J. Effectiveness and durability of
 a second COVID-19 booster against severe outcomes among older people in Norway: a population based cohort study comparing mono- and bivalent booster doses. International Journal of
 Epidemiology 2023; :dyad114.
- 401 36. Surie D. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated
 402 Hospitalization Among Immunocompetent Adults Aged ≥65 Years IVY Network, 18 States,
 403 September 8–November 30, 2022. MMWR Morb Mortal Wkly Rep 2022; 71. Available at:
 404 https://www.cdc.gov/mmwr/volumes/71/wr/mm715152e2.htm. Accessed 3 October 2023.

- Tan CY, Chiew CJ, Pang D, et al. Effectiveness of bivalent mRNA vaccines against medically attended
 symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive
 and previously infected individuals: a retrospective cohort study. The Lancet Infectious Diseases 2023;
- 407 and previously infected individuals: a retrospective cohort study. The Lancet Infectious Diseases 2023;
 408 0. Available at: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00373-0/fulltext.
 409 Accessed 1 October 2023.
- 38. Tenforde MW. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–
 Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among
 Immunocompetent Adults VISION Network, Nine States, September–November 2022. MMWR Morb
 Mortal Wkly Rep 2023; 71. Available at: https://www.cdc.gov/mmwr/volumes/71/wr/mm7153a1.htm.
 Accessed 3 October 2023.
- 41539.Tseng HF, Ackerson BK, Sy LS, et al. mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine416effectiveness against COVID-19 outcomes in the United States. Nat Commun **2023**; 14:5851.
- 40. Mimura W, Ishiguro C, Terada-Hirashima J, et al. Bivalent Vaccine Effectiveness Among Adults Aged ≥65
 418 Years During the BA.5-Predominant Period in Japan: The VENUS Study. Open Forum Infectious Diseases
 419 2023; 10:ofad475.
- 41. Tartof SY, Slezak JM, Puzniak L, et al. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against
 a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
 The Lancet Respiratory Medicine **2023**; 11:1089–1100.
- 42. Rudolph AE, Khan FL, Shah A, et al. Effectiveness of BNT162b2 BA.4/5 Bivalent mRNA Vaccine Against
 424 Symptomatic COVID-19 Among Immunocompetent Individuals Testing at a Large US Retail Pharmacy.
 425 The Journal of Infectious Diseases **2023**; :jiad474.
- 43. Fabiani M, Mateo-Urdiales A, Sacco C, et al. Relative effectiveness of bivalent Original/Omicron BA.4-5
 427 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2
 428 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023. Euro Surveill **2023b**;
 429 28:2300397.
- 43. Kim RK, Choe YJ, Jang EJ, et al. Comparative Effectiveness of COVID-19 Bivalent Versus Monovalent
 43. mRNA Vaccines in the Early Stage of Bivalent Vaccination in Korea: October 2022 to January 2023. J
 432 Korean Med Sci 2023; 38:e396.
- 433 45. Plumb ID, Briggs Hagen M, Wiegand R, et al. Effectiveness of a bivalent mRNA vaccine dose against
 434 symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022–May 2023.
 435 Vaccine 2023; Available at: https://www.sciencedirect.com/science/article/pii/S0264410X23012872.
 436 Accessed 4 January 2024.
- 437 46. Chalkias S, Harper C, Vrbicky K, et al. A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
 438 New England Journal of Medicine **2022**; 387:1279–1291.
- 439 47. Springer DN, Bauer M, Medits I, et al. Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5)
 440 increases neutralization of matched Omicron variants. npj Vaccines **2023**; 8:1–4.
- 48. Chen S-Y, Lin C-Y, Chi H, et al. The Effectiveness of Bivalent COVID-19 Vaccination: A Preliminary Report.
 442 Life **2023**; 13:2094.

- 443 49. Sadarangani M, Abu Raya B, Conway JM, et al. Importance of COVID-19 vaccine efficacy in older age
 444 groups. Vaccine 2021; 39:2020–2023.
- Lin D-Y, Gu Y, Xu Y, et al. Association of Primary and Booster Vaccination and Prior Infection With SARSCoV-2 Infection and Severe COVID-19 Outcomes. JAMA **2022**; 328:1415–1426.
- 447 51. Regan JJ. Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months:
- 448 Recommendations of the Advisory Committee on Immunization Practices United States, September
 449 2023. MMWR Morb Mortal Wkly Rep 2023; 72. Available at:
- 450 https://www.cdc.gov/mmwr/volumes/72/wr/mm7242e1.htm. Accessed 13 October 2023.

451

453 Figure Legend

454 Figure 1. Summary of evidence search and selection.

455

- 456 Figure 2. Forest plot for relative effectiveness of bivalent vaccines compared to different reference vaccine
- 457 groups against any infection or symptomatic infection for all ages. Statistics Cochran's Q, I² and τ^2 measure
- the heterogeneity between studies. End points of the studies are either symptomatic infection (SI) or any
- 459 infection (AI). TND: test-negative design study. cohort: cohort study. NA: not applicable. Mixed: containing
- 460 non-mRNA and mRNA monovalent vaccines. $\geq 2^*$: the majority ($\geq 80\%$) received 2 or more doses.

461


- 462 Figure 3. Forest plot for relative effectiveness of bivalent vaccines compared to different reference vaccine
- 463 groups against any infection or symptomatic infection for senior adults \geq 60 years old. Statistics Cochran's Q,
- 464 I^2 and τ^2 measure the heterogeneity between studies. End points of the studies are either symptomatic
- 465 infection (SI) or any infection (AI). TND: test-negative design study. cohort: cohort study. NA: not applicable.
- 466 Mixed: containing non-mRNA and mRNA monovalent vaccines.

467

- 468 Figure 4. Forest plot for relative effectiveness of bivalent vaccines compared to different reference vaccine
- 469 groups against severe outcomes for all ages. Statistics Cochran's Q, I2 and τ^2 measure the heterogeneity
- 470 between studies. End points of the studies are hospitalization (H), Death (D), hospitalization or death (H/D),
- 471 severe disease or death (SD/D). TND: test-negative design study. cohort: cohort study. NA: not applicable. NS:
- 472 not specified. Mixed: containing non-mRNA and mRNA monovalent vaccines.

- 474 Figure 5. Forest plot for relative effectiveness of bivalent vaccines compared to different reference vaccine
- groups against severe outcomes for senior adults ≥ 60 years old. Statistics Cochran's Q, I2 and τ^2 measure the
- 476 heterogeneity between studies. End points of the studies are hospitalization (H), Death (D), hospitalization or
- 477 death (H/D), severe disease or death (SD/D). TND: test-negative design study. cohort: cohort study. NA: not
- 478 applicable. Mixed: containing non-mRNA and mRNA monovalent vaccines.

Identification of studies via databases



Identification

Screening

Included

Figure 1. Summary of evidence search and selection

Fig 2. Forest Plot for Bivalent COVID-19 Vaccines Effectiveness against All Infection or Symptomatic Infection, All Ages

Author(s) and Year	Region	Circulating Subvariant	Study Design	Bivalent Dose	Bivalent Type	Monovalent Dose	Monovalent Type	Event Type	Age Group (years)	Test Time (days)	
Reference: unvaccinated	d										
Arashiro, et al. (2023)	JPN	BA.5	TND	≥3	BA.1 or BA.4-	5 0	NA	SI	≥16	≥14	
Rudolph, et al. (2023)	USA	BA.4/5, XBB	TND	≥3	BA.4-5	0	NA	SI	≥18	≥14	I
Pooled VE for all ages: (0	Q = 27.86	6, df = 1, p < .01; I ²	= 96.4%,	$\tau^2 = 4.706$	∋-01)				-		
Reference: 2 or more do	ses of n	nonovalent vaccin	es								
Kim, et al. (2023)	KOR	BQ, XBB	cohort	≥3	BA.4-5	≥2	Mixed	AI	≥18	≥14	
Rudolph, et al. (2023)	USA	BA.4/5, XBB	TND	≥3	BA.4-5	≥2	mRNA	SI	≥18	≥14	
Plumb, et al. (2023)	USA	BA.5	TND	≥3	BA.1 or BA.4-	5 ≥2	Mixed	SI	≥18	≥7	
Arashiro, et al. (2023)	JPN	BA.5	TND	≥3	BA.1 or BA.4-	5 ≥2*	mRNA	SI	≥16	≥14	F
Chemaitelly, et al. (2023)	QAT	XBB	cohort	≥3	BA.1	≥2	Mixed	AI	all ages	≥7	
Shrestha, et al. (2023)	USA	BA.4/5, BQ, XBB	cohort	≥2*	BA.4-5	≥2*	Mixed	AI	≥18	≥7	- -
Lin, et al. (2023)	USA	BQ.1, XBB	cohort	≥3	BA.1	≥2	Mixed	AI	≥12	7-105	
Pooled VE for all ages: (0	ຊ = 3115	.46, df = 6, p < .01;	$I^2 = 99.4$	%, τ ² = 1.9	97e-02)						
Reference: 3 or more do	ses of n	nonovalent vaccin	es								
Tan, et al. (2023)	SGP	XBB	cohort	4	BA.1 or BA.4-	5 3	Mixed	SI	≥18	7-90	
Mimura, et al. (2023)	JPN	BA.5	cohort	≥4	BA.1 or BA.4-	5 ≥3	mRNA	SI	≥65	≥14	
Plumb, et al. (2023)	USA	BA.5	TND	4	BA.1 or BA.4-	5 3	Mixed	SI	≥18	≥7	F
Kim, et al. (2023)	KOR	BQ, XBB	cohort	4	BA.4-5	3	Mixed	AI	≥18	≥14	
Huiberts, et al. (2023)	NLD	BA.5	cohort	≥3	BA.1	≥3	Mixed	AI	18-85	≥8	-
Chae, et al. (2023)	KOR	BA.5, BN.1, XBB	cohort	≥3	BA.1 or BA.4-	5 ≥3	Mixed	AI	≥18	≥14	├──■──┤
Auvigne, et al. (2023)	FRA	BA.5, BQ.1.1	cohort	≥3	BA.4-5	≥3	mRNA	SI	≥60	≥7	
Pooled VE for all ages: (0	ຊ = 2212	63, df = 6, p < .01;	$I^2 = 99.7$	%, $\tau^2 = 3.6$	61e-01)						
Pooled VE for all ages ren	noving T	an, et al. (2023):(Q = 150.8	9, df = 5, p	o < .01; I ² = 98.	2%, τ ² = 7.71	e-02)				

Pooled VE for all ages across all reference vaccination groups: (Q = 5838.27, df = 15, p < .01; I^2 = 99.9%, τ^2 = 1.96e-01)

Pooled VE for all ages across all reference vaccination groups removing Tan, et al. (2023): (Q = 3317.73, df = 14, p < .01; I^2 = 99.7%, τ^2 = 6.75e-02) Test for VE difference for all ages across all reference vaccination groups: Q_M = 1.21, df = 2, p = 0.55

Test for VE difference for all ages across all reference vaccination groups removing Tan, et al. (2023): Q_M = 2.70, df = 2, p = 0.26




Fig 3. Forest Plot for Bivalent COVID-19 Vaccines Effectiveness against All Infection or Symptomatic Infection, Senior Ages (≥ 60 years old)

Author(s) and Year	Region	Circulating Subvariant	Study Design	Bivalent Dose	Bivalent Type	Monovalent Dose	Monovalent Type	Event / Type	Age Group (years)	Test Time (days)		
Reference: unvaccinated												
Rudolph, et al. (2023)	USA	BA.4/5, XBB	TND	≥3	BA.4-5	0	NA	SI	≥65	≥14	⊢_	
Reference: 2 or more doses of monovalent vaccines												
Rudolph, et al. (2023)	USA	BA.4/5, XBB	TND	≥3	BA.4-5	≥2	mRNA	SI	≥65	≥14		
Reference: 3 or more a	loses of m	onovalent vaccii	nes									
Tan, et al. (2023)	SGP	XBB	cohort	4	BA.1 or BA.4-	5 3	Mixed	SI	≥60	7-90		
Mimura, et al. (2023)	JPN	BA.5	cohort	≥4	BA.1 or BA.4-	5 ≥3	mRNA	SI	≥65	≥14		
Huiberts, et al. (2023)	NLD	BA.5	cohort	≥3	BA.1	≥3	Mixed	AI	60-85	≥8	F	
Auvigne, et al. (2023)	FRA	BA.5, BQ.1.1	cohort	≥3	BA.4-5	≥3	mRNA	SI	≥60	≥7		
Pooled VE for senior age	es: (Q = 58	80.91, df = 3, p < .	01; I ² = 99	9.4%, τ ² =	4.98e-01)					_		
Pooled VE for senior age	es removino	g Tan, et al. (2023	3): (Q = 12	20.01, df =	= 2, p < .01; l ² =	98.4%, τ ² =	1.84e-01)					
Pooled VE for senior ages across all reference vaccination groups: (Q = 646.43, df = 5, p < .01; I^2 = 99.3%, τ^2 = 3.33e-01)												
Pooled VE for senior ages across all reference vaccination groups removing Tan, et al. (2023): (Q = 124.08, df = 4, p < .01; I^2 = 97.5%, τ^2 = 9.30e-02)												
Test for VE difference for senior ages across all reference vaccination groups: $Q_M = 0.35$, df = 2, p = 0.84												

Test for VE difference for senior ages across all reference vaccination groups removing Tan, et al. (2023): Q_M = 0.06, df = 2, p = 0.97

Estimate [95% CI]




Fig 4. Forest Plot for Bivalent COVID-19 Vaccines Effectiveness against Severe Outcomes, All Ages

Author(s) and Year	Regior	Circulating Subvariant	Study Design	Bivalent Dose	Bivalent Type	Monovalent Dose	Monovalent Type	Event Type	Age Group (years)
Reference: unvaccinated									
Grewal, et al. (2023)	CAN	BA.4/5, BQ.1	TND	≥4	BA.1	0	NA	H/D	≥50
Surie, et al. (2022)	USA	BA.5, BQ.1	TND	≥3	BA.4-5	0	NA	Н	≥65
Tseng, et al. (2023)	USA	BA.4/5	cohort	≥3	BA.4-5	0	NA	Н	≥6
Lee, et al. (2023)	CAN	BQ, XBB	TND	5	BA.1 or BA.4-5 (>99	%) 0	NA	H/D	≥50
Tenforde, et al. (2023)	USA	BA.5	TND	≥3	BA.4-5	0	NA	Н	≥18
Tartof, et al. (2023)	USA	BA.4/5, XBB	TND	≥3	BA.4-5	0	NA	Н	≥18
Link-Gelles, et al. (2023)	USA	BA.4/5, XBB	TND	≥3	BA.1 or BA.4-5	0	NA	Н	≥18
Pooled VE for all ages: $(Q = 2)$	272.89, d	lf = 6, p < .01; l ² = 97.4%, τ ²	= 2.33e-0	1)					
Reference: 2 or more doses	of mone	ovalent vaccines							
Kim, et al. (2023)	KOR	BQ, XBB	cohort	≥3	BA.4-5	≥2	Mixed	SD/D	≥18
Arbel, et al. (2023)	ISR	BA.5, BQ.1	cohort	≥3	BA.4-5	≥2	mRNA	Н	≥65
Tseng, et al. (2023)	USA	BA.4/5	cohort	≥3	BA.4-5	≥2	mRNA	Н	≥6
Tenforde, et al. (2023)	USA	BA.5	TND	≥3	BA.4-5	≥2	mRNA	Н	≥18
Lin, et al. (2023)	USA	BQ.1, XBB	cohort	≥3	BA.1	≥2	Mixed	Н	≥12
Kirsebom, et al. (2023a)	GBR	BA.5, BQ.1, CH.1.1, XBB.1	I.5TND	≥3	BA.1	≥2	Mixed	Н	≥50
Tartof, et al. (2023)	USA	BA.4/5, XBB	TND	≥3	BA.4-5	≥2	mRNA	Н	≥18
Kirsebom, et al. (2023b)	GBR	BQ.1, CH.1.1, XBB.1.5	TND	≥3	BA.1	≥2	Mixed	Н	≥50
Pooled VE for all ages: $(Q = 2)$	135.61, d	lf = 7, p < .01; l ² = 98.8%, τ ²	= 1.85e-0	1)					
Reference: 3 or more doses	of mone	ovalent vaccines							
Tan, et al. (2023)	SGP	XBB	cohort	4	BA.1 or BA.4-5	3	Mixed	Н	≥18
Mimura, et al. (2023)	JPN	BA.5	cohort	≥4	BA.1 or BA.4-5	≥3	mRNA	Н	≥65
Stecher, et al. (2023)	NOR	BA, BQ, XBB	cohort	4	BA.1 or BA.4-5	3	Mixed	D	≥75
Tseng, et al. (2023)	USA	BA.4/5	cohort	≥3	BA.4-5	3	mRNA	Н	≥6
Andersson, et al. (2023)	DFNS	BA.5, BQ, BF, XBB	cohort	4	BA.1 or BA.4-5	3	mRNA	Н	≥50
Kim, et al. (2023)	KOR	BQ, XBB	cohort	4	BA.4-5	3	Mixed	SD/D	≥60
Fabiani, et al. (2023a)	ITA	BA.5	cohort	4	BA.4-5	3	mRNA	H/D	≥60
Fabiani, et al. (2023b)	ITA	XBB	cohort	≥4	BA.4-5	3	mRNA	H/D	≥80
Mateo-Urdiales, et al. (2023)	ITA	BA.5	cohort	4	BA.1 or BA.4-5	3	mRNA	H/D	≥60
Chatzilena, et al. (2023)	GBR	BA.4/5, BQ.1, CH.1.1, XB	B TND	5	BA.1	4	mRNA	Н	≥75
Pooled VE for all ages: $(Q = 2)$	101.12, d	lf = 9, p < .01; l ² = 96.1%, τ ²	= 2.10e-0	1)					
Pooled VE for all ages removi	ng Tan, e	et al. (2023): (Q = 50.36, df	= 8, p < .0 ⁻	1; I ² = 83.3°	%, τ ² = 3.89e-02)				

Pooled VE for all ages across all reference vaccination groups: (Q = 894.36, df = 24, p < .01; I^2 = 98.4%, τ^2 = 2.23e-01)

Pooled VE for all ages across all reference vaccination groups removing Tan, et al. (2023): (Q = 836.93, df = 23, p < .01; I^2 = 98.0%, τ^2 = 1.75e-01)

Test for VE difference for all ages across all reference vaccination groups: $Q_M = 3.49$, df = 2, p = 0.17

Test for VE difference for all ages across all reference vaccination groups removing Tan, et al. (2023): Q_M = 4.35, df = 2, p = 0.11




Fig 5. Forest Plot for Bivalent COVID-19 Vaccines Effectiveness against Severe Outcomes, Senior Ages (≥ 60 years old)

Region	Circulating Subvariant	Study Design	Bivalent Dose	Bivalent Type	Monovalent Dose	Monovalent Type	Event Type	Age Group (years)
USA	BA.5, BQ.1	TND	≥3	BA.4-5	0	NA	Н	≥65
USA	BA.4/5	cohort	≥3	BA.4-5	0	NA	Н	≥65
USA	BA.4/5, XBB	TND	≥3	BA.1 or BA.4-5	0	NA	Н	≥65
USA	BA.4/5, XBB	TND	≥3	BA.4-5	0	NA	н	≥65
= 62.28,	df = 3, p < .01; l ² = 95.1%,	, τ ² = 2.75e	-01)					
of monov	valent vaccines							
ISR	BA.5, BQ.1	cohort	≥3	BA.4-5	≥2	mRNA	Н	≥65
USA	BA.4/5	cohort	≥3	BA.4-5	≥2	mRNA	н	≥65
USA	BA.4/5, XBB	TND	≥3	BA.4-5	≥2	mRNA	н	≥65
= 19.24,	df = 2, $p < .01$; $I^2 = 89.0\%$,	, τ ² = 1.57e	-01)					
of monov	valent vaccines							
JPN	BA.5	cohort	≥4	BA.1 or BA.4-5	≥3	mRNA	н	≥65
NOR	BA, BQ, XBB	cohort	4	BA.1 or BA.4-5	3	Mixed	D	≥75
DFNS	BA.5, BQ, BF, XBB	cohort	4	BA.1 or BA.4-5	3	mRNA	н	≥70
KOR	BQ, XBB	cohort	4	BA.4-5	3	Mixed	SD/D	≥60
ITA	BA.5	cohort	4	BA.4-5	3	mRNA	H/D	≥60
ITA	XBB	cohort	≥4	BA.4-5	3	mRNA	H/D	≥80
ITA	BA.5	cohort	4	BA.1 or BA.4-5	3	mRNA	H/D	≥60
GBR	BA.4/5, BQ.1, CH.1.1, XE	B TND	5	BA.1	4	mRNA	н	≥75
= 36.10,	df = 7, p < .01; l ² = 81.6%,	τ ² = 3.76e	-02)					
	USA USA USA USA = 62.28, of monov USA USA = 19.24, of monov JPN NOR DFNS KOR ITA ITA ITA ITA GBR	KeyonSubvariantUSABA.5, BQ.1USABA.4/5USABA.4/5, XBBUSABA.4/5, XBB= 62.28, df = 3, $p < .01; l^2 = 95.1\%$,of monovalent vaccinesISRBA.5, BQ.1USABA.4/5USABA.4/5, XBB= 19.24, df = 2, $p < .01; l^2 = 89.0\%$,of monovalent vaccinesJPNBA.5NORBA, BQ, XBBDFNSBA.5, BQ, BF, XBBKORBQ, XBBITABA.5ITAXBBITABA.5GBRBA.4/5, BQ.1, CH.1.1, XE	KegionSubvariantDesignUSABA.5, BQ.1TNDUSABA.4/5cohortUSABA.4/5, XBBTNDUSABA.4/5, XBBTNDUSABA.4/5, XBBTND= 62.28, df = 3, p < .01; l ² = 95.1%, τ^2 = 2.75eof monovalent vaccinesISRBA.5, BQ.1USABA.4/5LUSABA.4/5LUSABA.4/5LUSABA.4/5LUSABA.4/5LUSABA.4/5LUSABA.4/5LUSABA.4/5LUSABA.4/5LUSABA.4/5LUSABA.4/5LUSABA.4/5LUSABA.4/5LUSABA.4/5LUSABA.4/5LUSABA.5LUSACohortUSABA.5LUSABA.5LUSABA.5LUSABA.5LUSABA.5LUSABA.5LUSABA.4/5LUSABA.5 <td>KegionSubvariantDesignDoseUSABA.5, BQ.1TND≥ 3USABA.4/5, XBBTND≥ 3USABA.4/5, XBBTND≥ 3USABA.4/5, XBBTND≥ 3USABA.4/5, XBBTND≥ 3= 62.28, df = 3, p < .01; l² = 95.1%, $\tau^2 = 2.75e-01$)of monovalent vaccinesISRBA.5, BQ.1cohort≥ 3USABA.4/5cohort≥ 3USABA.4/5, XBBTND≥ 3USABA.4/5, XBBTND≥ 3USABA.4/5, XBBTND≥ 3= 19.24, df = 2, p < .01; l² = 89.0%, $\tau^2 = 1.57e-01$)of monovalent vaccinesJPNBA.5cohort4NORBA, BQ, XBBcohort4IFNSBA.5, BQ, BF, XBBcohort4ITABA.5cohort4ITABA.5cohort4ITABA.5cohort4</td> <td>KegionSubvariantDesignDoseTypeUSABA.5, BQ.1TND≥ 3BA.4-5USABA.4/5cohort≥ 3BA.4-5USABA.4/5, XBBTND≥ 3BA.1 or BA.4-5USABA.4/5, XBBTND≥ 3BA.1 or BA.4-5USABA.4/5, XBBTND≥ 3BA.4-5isaBA.4/5, XBBTND≥ 3BA.4-5isaBA.5, BQ.1cohort≥ 3BA.4-5USABA.4/5cohort≥ 3BA.4-5USABA.4/5cohort≥ 3BA.4-5USABA.4/5, XBBTND≥ 3BA.4-5USABA.4/5, XBBTND≥ 3BA.4-5USABA.4/5, XBBTND≥ 3BA.4-5USABA.4/5, XBBTND≥ 3BA.4-5USABA.4/5, XBBTND≥ 3BA.4-5isaBA.4/5, XBBTND≥ 3BA.4-5USABA.4/5, XBBTND≥ 3BA.4-5USABA.4/5, XBBTND≥ 4BA.4-5isaBA.5, BQ, BF, XBBcohort≥ 4BA.1 or BA.4-5DFNSBA.5, BQ, BF, XBBcohort4BA.4-5ITABA.5cohort4BA.4-5ITABA.5cohort≥ 4BA.4-5ITABA.5cohort≥ 4BA.4-5ITABA.5cohort≥ 4BA.4-5ITABA.5cohort≥ 4</td> <td>KegionSubvariantDesignDoseTypeDoseUSABA.5, BQ.1TND≥ 3BA.4-50USABA.4/5cohort≥ 3BA.4-50USABA.4/5, XBBTND≥ 3BA.1 or BA.4-50USABA.4/5, XBBTND≥ 3BA.1 or BA.4-50USABA.4/5, XBBTND≥ 3BA.4-50= 62.28, df = 3, p < .01; l² = 95.1%, $\tau^2 = 2.75e-01$)$\rightarrow$$\rightarrow$of monovalent vaccinesISRBA.5, BQ.1cohort≥ 3BA.4-5≥ 2USABA.4/5, XBBTND≥ 3BA.4-5≥ 2USABA.4/5, XBBCohort≥ 3BA.4-5≥ 2USABA.4/5, XBBTND≥ 4BA.1 or BA.4-5≥ 2USABA.5, BQ, BF, XBBcohort4BA.4-53IFNSBA.5, BQ, BF, XBBcohort4BA.4-53IFABA.5cohort4BA.4-53ITABA.5cohort≥ 4BA.4-53<!--</td--><td>RegionSubvariantDesignDoseTypeDoseTypeUSABA.5, BQ.1TND≥ 3BA.4-50NAUSABA.4/5cohort≥ 3BA.4-50NAUSABA.4/5, XBBTND≥ 3BA.1 or BA.4-50NAUSABA.4/5, XBBTND≥ 3BA.4-50NAUSABA.4/5, XBBTND≥ 3BA.4-50NAUSABA.4/5, XBBTND≥ 3BA.4-50NAe62.28, df = 3, p < .01; 1² = 95.1%, $\tau^2 = 2.75e-01$)ofmonovalent vaccinesmRNAUSABA.4/5cohort≥ 3BA.4-5≥ 2mRNAUSABA.4/5, XBBTND≥ 3BA.4-5≥ 2mRNAUSABA.4/5, XBBTND≥ 3BA.4-5≥ 2mRNAUSABA.4/5, XBBTND≥ 3BA.4-5≥ 2mRNAUSABA.4/5, BB.0.1cohort≥ 3BA.4-5≥ 2mRNAUSABA.4/5, BB.0.1cohort≥ 3BA.4-5≥ 2mRNAUSABA.4/5, BB.0.1cohort≥ 4BA.1 or BA.4-5≥ 2mRNAUSABA.5, BQ, BF, XBBcohort$\neq 4$BA.1 or BA.4-5$\Rightarrow 3$mRNANORBA, BQ, XBBcohort4BA.1 or BA.4-5$\Rightarrow 3$mRNANORBA, SD, BF, XBBcohort4BA.4-5$\Rightarrow 3$mRNAITABA.5coho</td><td>RegionSubvariantDesignDoseTypeDoseTypeTypeUSABA.5, BQ.1TND≥ 3BA.4-50NAHUSABA.4/5cohort≥ 3BA.4-50NAHUSABA.4/5, XBBTND≥ 3BA.1 or BA.4-50NAHUSABA.4/5, XBBTND≥ 3BA.1 or BA.4-50NAHUSABA.4/5, XBBTND≥ 3BA.4-50NAHUSABA.4/5, XBBTND≥ 3BA.4-50NAHUSABA.4/5, XBBTND≥ 3BA.4-5≥ 2mRNAHUSABA.4/5cohort≥ 3BA.4-5≥ 2mRNAHUSABA.4/5cohort≥ 3BA.4-5≥ 2mRNAHUSABA.4/5cohort≥ 3BA.4-5≥ 2mRNAHUSABA.4/5, KBBTND≥ 3BA.4-5≥ 2mRNAHUSABA.4/5, KBBTND≥ 3BA.4-5≥ 2mRNAHUSABA.4/5, KBBTND≥ 3BA.4-5≥ 2mRNAHUSABA.4/5, KBBTND≥ 3BA.4-5≥ 2mRNAHUSABA.5, Cohort≥ 4BA.1 or BA.4-5≥ 3mRNAHNORBA, BQ, XBBcohort4BA.1 or BA.4-5$3$mRNAHNORBA, SBA, BQ, SE,</td></td>	KegionSubvariantDesignDoseUSABA.5, BQ.1TND ≥ 3 USABA.4/5, XBBTND ≥ 3 USABA.4/5, XBBTND ≥ 3 USABA.4/5, XBBTND ≥ 3 USABA.4/5, XBBTND ≥ 3 = 62.28, df = 3, p < .01; l ² = 95.1%, $\tau^2 = 2.75e-01$)of monovalent vaccinesISRBA.5, BQ.1cohort ≥ 3 USABA.4/5cohort ≥ 3 USABA.4/5, XBBTND ≥ 3 USABA.4/5, XBBTND ≥ 3 USABA.4/5, XBBTND ≥ 3 = 19.24, df = 2, p < .01; l ² = 89.0%, $\tau^2 = 1.57e-01$)of monovalent vaccinesJPNBA.5cohort4NORBA, BQ, XBBcohort4IFNSBA.5, BQ, BF, XBBcohort4ITABA.5cohort4ITABA.5cohort4ITABA.5cohort4	KegionSubvariantDesignDoseTypeUSABA.5, BQ.1TND ≥ 3 BA.4-5USABA.4/5cohort ≥ 3 BA.4-5USABA.4/5, XBBTND ≥ 3 BA.1 or BA.4-5USABA.4/5, XBBTND ≥ 3 BA.1 or BA.4-5USABA.4/5, XBBTND ≥ 3 BA.4-5isaBA.4/5, XBBTND ≥ 3 BA.4-5isaBA.5, BQ.1cohort ≥ 3 BA.4-5USABA.4/5cohort ≥ 3 BA.4-5USABA.4/5cohort ≥ 3 BA.4-5USABA.4/5, XBBTND ≥ 3 BA.4-5isaBA.4/5, XBBTND ≥ 3 BA.4-5USABA.4/5, XBBTND ≥ 3 BA.4-5USABA.4/5, XBBTND ≥ 4 BA.4-5isaBA.5, BQ, BF, XBBcohort ≥ 4 BA.1 or BA.4-5DFNSBA.5, BQ, BF, XBBcohort4BA.4-5ITABA.5cohort4BA.4-5ITABA.5cohort ≥ 4 BA.4-5ITABA.5cohort ≥ 4 BA.4-5ITABA.5cohort ≥ 4 BA.4-5ITABA.5cohort ≥ 4	KegionSubvariantDesignDoseTypeDoseUSABA.5, BQ.1TND ≥ 3 BA.4-50USABA.4/5cohort ≥ 3 BA.4-50USABA.4/5, XBBTND ≥ 3 BA.1 or BA.4-50USABA.4/5, XBBTND ≥ 3 BA.1 or BA.4-50USABA.4/5, XBBTND ≥ 3 BA.4-50= 62.28, df = 3, p < .01; l ² = 95.1%, $\tau^2 = 2.75e-01$) \rightarrow \rightarrow of monovalent vaccinesISRBA.5, BQ.1cohort ≥ 3 BA.4-5 ≥ 2 USABA.4/5, XBBTND ≥ 3 BA.4-5 ≥ 2 USABA.4/5, XBBCohort ≥ 3 BA.4-5 ≥ 2 USABA.4/5, XBBTND ≥ 4 BA.1 or BA.4-5 ≥ 2 USABA.5, BQ, BF, XBBcohort4BA.4-53IFNSBA.5, BQ, BF, XBBcohort4BA.4-53IFABA.5cohort4BA.4-53ITABA.5cohort ≥ 4 BA.4-53 </td <td>RegionSubvariantDesignDoseTypeDoseTypeUSABA.5, BQ.1TND≥ 3BA.4-50NAUSABA.4/5cohort≥ 3BA.4-50NAUSABA.4/5, XBBTND≥ 3BA.1 or BA.4-50NAUSABA.4/5, XBBTND≥ 3BA.4-50NAUSABA.4/5, XBBTND≥ 3BA.4-50NAUSABA.4/5, XBBTND≥ 3BA.4-50NAe62.28, df = 3, p < .01; 1² = 95.1%, $\tau^2 = 2.75e-01$)ofmonovalent vaccinesmRNAUSABA.4/5cohort≥ 3BA.4-5≥ 2mRNAUSABA.4/5, XBBTND≥ 3BA.4-5≥ 2mRNAUSABA.4/5, XBBTND≥ 3BA.4-5≥ 2mRNAUSABA.4/5, XBBTND≥ 3BA.4-5≥ 2mRNAUSABA.4/5, BB.0.1cohort≥ 3BA.4-5≥ 2mRNAUSABA.4/5, BB.0.1cohort≥ 3BA.4-5≥ 2mRNAUSABA.4/5, BB.0.1cohort≥ 4BA.1 or BA.4-5≥ 2mRNAUSABA.5, BQ, BF, XBBcohort$\neq 4$BA.1 or BA.4-5$\Rightarrow 3$mRNANORBA, BQ, XBBcohort4BA.1 or BA.4-5$\Rightarrow 3$mRNANORBA, SD, BF, XBBcohort4BA.4-5$\Rightarrow 3$mRNAITABA.5coho</td> <td>RegionSubvariantDesignDoseTypeDoseTypeTypeUSABA.5, BQ.1TND≥ 3BA.4-50NAHUSABA.4/5cohort≥ 3BA.4-50NAHUSABA.4/5, XBBTND≥ 3BA.1 or BA.4-50NAHUSABA.4/5, XBBTND≥ 3BA.1 or BA.4-50NAHUSABA.4/5, XBBTND≥ 3BA.4-50NAHUSABA.4/5, XBBTND≥ 3BA.4-50NAHUSABA.4/5, XBBTND≥ 3BA.4-5≥ 2mRNAHUSABA.4/5cohort≥ 3BA.4-5≥ 2mRNAHUSABA.4/5cohort≥ 3BA.4-5≥ 2mRNAHUSABA.4/5cohort≥ 3BA.4-5≥ 2mRNAHUSABA.4/5, KBBTND≥ 3BA.4-5≥ 2mRNAHUSABA.4/5, KBBTND≥ 3BA.4-5≥ 2mRNAHUSABA.4/5, KBBTND≥ 3BA.4-5≥ 2mRNAHUSABA.4/5, KBBTND≥ 3BA.4-5≥ 2mRNAHUSABA.5, Cohort≥ 4BA.1 or BA.4-5≥ 3mRNAHNORBA, BQ, XBBcohort4BA.1 or BA.4-5$3$mRNAHNORBA, SBA, BQ, SE,</td>	RegionSubvariantDesignDoseTypeDoseTypeUSABA.5, BQ.1TND ≥ 3 BA.4-50NAUSABA.4/5cohort ≥ 3 BA.4-50NAUSABA.4/5, XBBTND ≥ 3 BA.1 or BA.4-50NAUSABA.4/5, XBBTND ≥ 3 BA.4-50NAUSABA.4/5, XBBTND ≥ 3 BA.4-50NAUSABA.4/5, XBBTND ≥ 3 BA.4-50NAe62.28, df = 3, p < .01; 1 ² = 95.1%, $\tau^2 = 2.75e-01$)ofmonovalent vaccinesmRNAUSABA.4/5cohort ≥ 3 BA.4-5 ≥ 2 mRNAUSABA.4/5, XBBTND ≥ 3 BA.4-5 ≥ 2 mRNAUSABA.4/5, XBBTND ≥ 3 BA.4-5 ≥ 2 mRNAUSABA.4/5, XBBTND ≥ 3 BA.4-5 ≥ 2 mRNAUSABA.4/5, BB.0.1cohort ≥ 3 BA.4-5 ≥ 2 mRNAUSABA.4/5, BB.0.1cohort ≥ 3 BA.4-5 ≥ 2 mRNAUSABA.4/5, BB.0.1cohort ≥ 4 BA.1 or BA.4-5 ≥ 2 mRNAUSABA.5, BQ, BF, XBBcohort $\neq 4$ BA.1 or BA.4-5 $\Rightarrow 3$ mRNANORBA, BQ, XBBcohort4BA.1 or BA.4-5 $\Rightarrow 3$ mRNANORBA, SD, BF, XBBcohort4BA.4-5 $\Rightarrow 3$ mRNAITABA.5coho	RegionSubvariantDesignDoseTypeDoseTypeTypeUSABA.5, BQ.1TND ≥ 3 BA.4-50NAHUSABA.4/5cohort ≥ 3 BA.4-50NAHUSABA.4/5, XBBTND ≥ 3 BA.1 or BA.4-50NAHUSABA.4/5, XBBTND ≥ 3 BA.1 or BA.4-50NAHUSABA.4/5, XBBTND ≥ 3 BA.4-50NAHUSABA.4/5, XBBTND ≥ 3 BA.4-50NAHUSABA.4/5, XBBTND ≥ 3 BA.4-5 ≥ 2 mRNAHUSABA.4/5cohort ≥ 3 BA.4-5 ≥ 2 mRNAHUSABA.4/5cohort ≥ 3 BA.4-5 ≥ 2 mRNAHUSABA.4/5cohort ≥ 3 BA.4-5 ≥ 2 mRNAHUSABA.4/5, KBBTND ≥ 3 BA.4-5 ≥ 2 mRNAHUSABA.5, Cohort ≥ 4 BA.1 or BA.4-5 ≥ 3 mRNAHNORBA, BQ, XBBcohort4BA.1 or BA.4-5 3 mRNAHNORBA, SBA, BQ, SE,

Pooled VE for senior ages across all reference vaccination groups: (Q = 133.47, df = 14, p < .01; I^2 = 93.3%, τ^2 = 1.15e-01)

Test for VE difference for senior ages across all reference vaccination groups: $Q_M = 1.19$, df = 2, p = 0.55

